EYPT · EyePoint, Inc. · Investor Relations
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-09-16 |
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new |
| 2026-09-02 |
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following |
| 2026-08-17 |
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 letters) unrelated to wet AMD; primary endpoint not achieved in full dataset, confounded by this |
| 2026-08-14 |
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new |
| 2026-08-05 |
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 –– – Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 –– – Pivotal Phase 3 DME clinical trials, COMO and CAPRI, fully enrolled over 480 patients in 5 months; topline data |
| 2026-07-30 |
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
– COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients –– – Topline 56-week data for both DME trials anticipated in 4Q 2027 – WATERTOWN, Mass., July 30, 2026 |
| 2026-07-16 |
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new |
| 2026-07-13 |
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives WATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing |
| 2026-06-16 |
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new |
| 2026-05-19 |
EyePoint Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-15 | Morgan Stanley Global Healthcare Conference | Conference |
| 2026-09-10 | Cantor Global Healthcare Conference 2026 | Conference |
| 2026-09-09 | Citi 2026 Biopharma Back to School Conference | Conference |
| 2026-08-17 | EyePoint: LUGANO Topline Data | Webcast |
| 2026-08-17 | Earnings conference call (announced in 8-K) | Earnings call |
| 2026-06-09 | Goldman Sachs 47th Annual Global Healthcare Conference | Conference |
| 2026-06-03 | Jefferies Global Healthcare Conference | Conference |
| 2026-05-26 | Stifel 2026 Virtual Ophthalmology Forum | Event |
| 2026-05-06 | EyePoint First Quarter 2026 Financial Results Conference Call | Earnings call |
| 2026-03-25 | RBC Capital Markets Virtual Ophthalmology Conference | Conference |
| 2026-03-04 | Q4 Earnings conference call (announced in 8-K) | Earnings call |
| 2026-03-04 | EyePoint Fourth Quarter 2025 Financial Results Conference Call | Earnings call |
Source: https://investors.eyepoint.bio/